MetaVia Inc. (MTVA)

NCM – Real vaqt narxi. Valyuta: USD

1.43

-0.10 (-6.54%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.43

+0.00 (0.01%)

Bozordan keyin: Jun 26, 2026, 7:44 PM EDT

09.06.2026

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D.

08.06.2026

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model Vanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D Model CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association's (ADA) 2026 Scientific Sessions, held June 5–8 in New Orleans, Louisiana.

04.06.2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.

27.05.2026

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose Levels CAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Association for the Study of the Liver Congress 2026 (EASL 2026), being held May 27–30 in Barcelona, Spain.

20.05.2026

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in the peer-reviewed, international journal, Biomolecules & Therapeutics.

18.05.2026

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that three late-breaking abstracts highlighting its cardiometabolic assets, DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, and vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, have been accepted for poster presentations at the American Diabetes Association's (ADA) 2026 Scientific Sessions.

14.05.2026

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Patient in Phase 1 Part 3 16-Week Titration Study Evaluating 48 mg (1-Step) and 64 mg (2-Step) Regimens; Data Expected in Fourth Quarter 2026 CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate strategic update.

Videolar

No Data

There is no data to display

Press-relizlar

09.06.2026

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

08.06.2026

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

04.06.2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

27.05.2026

MetaVia Inc. (MTVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

MetaVia Inc. (MTVA)

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

Search stocks

MetaVia Inc. (MTVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

MetaVia Inc. (MTVA)

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

Videolar

No Data

Press-relizlar

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH